

LISTING OF THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A P2X7 purinergic receptor antagonist for the treatment of multiple sclerosis demyelinating and autoimmune diseases in mammals wherein the antagonist is selected from the group consisting of Evans Blue, NF279, BBG, o-ATP, KN62, TNP-ATP and HMA.
2. (Previously Presented) The P2X7 purinergic receptor antagonist of claim 1, wherein the antagonist is o-ATP.
3. (Currently Amended) A method for preparing a drug for the treatment of multiple sclerosis demyelinating and autoimmune diseases in mammals, which method comprises incorporating in said drug ~~an effective amount of~~ a P2X7 purinergic receptor antagonist, wherein the antagonist is selected from the group consisting of Evans Blue, NF279, BBG, o-ATP, KN62, TNP-ATP and HMA.
4. (Previously Presented) The method of claim 3 wherein the antagonist is o-ATP.
5. (Currently Amended) A pharmaceutical composition for treating multiple sclerosis wherein the composition ~~which~~ comprises at least one P2X7 purinergic receptor antagonist and at least one pharmaceutically acceptable excipient, wherein the antagonist is selected from the group consisting of Evans Blue, NF279, BBG, o-ATP, KN62, TNP-ATP and HMA.
6. (Previously Presented) The pharmaceutical composition of claim 5, wherein the antagonist is o-ATP.

Claims 7-9 (Cancelled).